Doctors Backing Off Pfizer’s Paxlovid for Lower-Risk COVID Patients

Use of Pfizer Inc’s COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned  symptoms can recur after people complete a course of the drug.

Related articles

You may also be interested in

Headline

Never Miss A Story

Get our Weekly recap with the latest news, articles and resources.
Cookie policy

We use our own and third party cookies to allow us to understand how the site is used and to support our marketing campaigns.